You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Patient characteristics when starting a first suppression episode or a first subsequent suppression episode. Patients had to be antiretroviral treatment naive before achieving viral suppression on a first combination antiretroviral regimen. Viral suppression had to be recorded using a more sensitive assay: ultrasensitive versions of the Amplicor assay (if the lower limit of detection was recorded as <50 copies/ml), the Abbott RealTime assay, and the TaqMan assay versions 1 and 2

From: Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study

Characteristic Suppression episode
  First (4094 patients) First subsequent (1672 patientsa)
Female (%) 27 34
Injection drug use (%)b 9 17
Age (median, years) 40 43
CD4 cell count (median, cells/μL) 430 460
Year (%)   
 Before 2005 10 10
 2005 to 2009 46 55
 After 2009 45 35
Assay (%)c   
 Roche Amplicor ultrasensitive 12 14
 Abbot RealTime 1 1
 Roche TaqMan version 1 37 45
 Roche TaqMan version 2 50 41
cART class (%)   
 NNRTI 42 31
 Boosted PI 47 47
 Single PI 4 7
 Entry or integrase inhibitor 4 7
 Otherd 3 7
Magnitude of first blip (%)   
 No blips 78 72
 Low (50–199 copies/mL) 19 23
 Medium (200–499 copies/mL) 2 4
 High (500–999 copies/mL) 1 2
Number of blips (%)   
 None 78 72
 One 16 20
 Two 4 6
 Three or more 2 2
Viral rebound (%) 19 33
  1. cART combination antiretroviral therapy; NNRTI non-nucleoside reverse transcriptase inhibitor; PI protease inhibitor
  2. aPatients that had a subsequent suppression episode measured using acceptable assays did not always have a first suppression episode measured using acceptable assays
  3. bInjection drug use as the most likely mode of HIV infection
  4. cFirst use of each assay in these data: Roche Amplicor ultrasensitive, 1997; Abbot RealTime, 2009; Roche TaqMan version 1, 2002; Roche TaqMan version 2, 2006. Common use of each assay in these data (10th to 90th percentiles): Roche Amplicor ultrasensitive, 2000–05; Abbot RealTime, 2009–12; Roche TaqMan version 1, 2006–09; Roche TaqMan version 2, 2009–13 (current)
  5. dOther: More than one PI (other than ritonavir), a PI and an NNRTI, or three nucleoside or nucleotide reverse transcriptase inhibitors. The later was considered cART only if it followed an earlier cART regimen